According to a recent LinkedIn post from ThinkCyte, the company is actively engaging with potential customers and partners at the SLAS 2026 conference in Boston. The post highlights on-floor demonstrations of its Ghost Cytometry platform, which combines high-speed, label-free cell sorting with real-time AI analysis aimed at drug discovery and phenotypic screening workflows.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post also points to two scientific posters featuring VisionSort morphometric applications in immune cell phenotyping and senescence biomarker research. For investors, this presence suggests an effort to deepen adoption in cell analysis, flow cytometry, and drug discovery markets, potentially expanding ThinkCyte’s commercial pipeline and reinforcing its positioning in AI-enabled biological research tools.